Theramex and Enzene Biosciences announce tocilizumab agreement

Dec 23, 2021

Theramex and Enzene Biosciences announced that they have entered into an agreement for the development and commercialisation of biosimilar tocilizumab.  The product will be available in parenteral vials, PFS and autoinjectors from 2026 in Europe, the UK, Switzerland and Australia.

Print Page Mail Article